THERATECHNOLOGIES INC THTX 深 滬
已收盤 09-25 16:00:00 美东时间
3.39
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 3.39
- 總市值 1.56亿
- 52周最高 3.40
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.12
- 委 比 0.00%
- 總股本 4598.00万
- 歷史最高 17.84
- 量 比 0
- 振 幅 0.00%
- 歷史最低 1.08
- 每 手 1
- 風險率 0.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Theratechnologies Announces Completion of Acquisition by Future Pak
Theratechnologies Inc. announced the completion of its arrangement under the Business Corporations Act, where CB Biotechnology, an affiliate of Future Pak, acquired all its outstanding common shares at US$3.01 per share in cash plus one contingent value right (CVR) per share. This transaction, valued at US$0.80 per CVR as of September 24, 2025, allows for additional payments of up to US$1.19 per CVR if certain milestones are met. The shares are e...
2025-09-25 17:21
Theratechnologies Obtains Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak; Co. Expects That The Arrangement Will Be Completed On Or About September 25, 2025
MONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that the
2025-09-17 05:13
Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
Theratechnologies Inc. has received final court approval for its previously announced plan of arrangement involving Future Pak affiliate CB Biotechnology, LLC. Shareholders approved the arrangement at a special meeting on September 12, 2025, and the transaction is expected to close on or around September 25, 2025, pending remaining conditions. Theratechnologies is a biopharmaceutical company focused on innovative therapies, while Future Pak, foun...
2025-09-16 21:10
Theratechnologies Shareholders Approve Acquisition By CB Biotechnology
Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that its shareholders have approved the
2025-09-12 23:29
Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy
Theratechnologies announced the availability of EGRIFTA WR™ (tesamorelin) for injection to reduce excess abdominal fat in HIV patients with lipodystrophy. The new formulation offers weekly reconstitution and reduced injection volume compared to EGRIFTA SV®. Approved by the FDA earlier this year, EGRIFTA WR™ aims to simplify treatment and enhance user experience. Specialty pharmacies are now filling prescriptions for the new product, while EGRIFTA...
2025-09-05 11:30
Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak
Theratechnologies Inc. announced that leading proxy advisory firms ISS and Glass Lewis recommend shareholders vote FOR the Arrangement to approve a plan involving CB Biotechnology. The transaction offers US$3.01 per share in cash plus contingent value rights with potential additional payments. The Board has also unanimously recommended the Arrangement, stating it is in the best interests of the Company. Shareholders are encouraged to review the c...
2025-09-02 11:30
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
Theratechnologies Inc. announced the filing and mailing of a management proxy circular regarding a special shareholders' meeting to vote on its proposed acquisition by Future Pak. Shareholders will receive a cash premium of US$3.01 per share, plus a contingent value right (CVR) offering up to US$1.19 per share. The board unanimously recommends voting "FOR" the arrangement. The voting deadline is September 10, 2025, and the meeting will be held on...
2025-08-18 11:30
Theratechnologies Reports Q2 2025 Earnings and Acquisition
Theratechnologies ( ($THTX) ) has released its Q2 earnings. Here is a breakdown...
2025-07-10 11:50
Theratechnologies Q2 EPS $(0.09) Misses $(0.02) Estimate, Sales $17.729M Beat $17.547M Estimate
Theratechnologies (NASDAQ:THTX) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.02) by 350 percent. This is a 550 percent decrease over earnings of $0.02 per share from
2025-07-09 21:30
Theratechnologies reports Q2 results
Theratechnologies press release (NASDAQ:THTX): Q2 net loss of $4.42M. Revenue of $17.73M (-19.5% Y/Y) beats by $0.21M. More on Theratechnologies Inc. Theratechnologies: Beyond GLP-1s - Is Tesamorelin'...
2025-07-09 19:39
